Evidence map›Paper›PMID 29669588›Full record

ArticleJournal of hematology & oncology2018

Correction to: miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a.

Man-Qing Cao, A-Bin You, Xiao-Dong Zhu, Wei Zhang, Yuan-Yuan Zhang, Shi-Zhe Zhang, Kei-Wei Zhang, Hao Cai, Wen-Kai Shi, Xiao-Long Li and 9 more

Abstract readPublished Erratum
In one paragraph

Article in Journal of hematology & oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. The role of AURKA/miR-199b-3p in hepatocellular carcinoma cells.Journal of clinical laboratory analysis · 2022
    Article
  5. Review
  6. miR-182-5p Serves as an Oncogene in Lung Adenocarcinoma through Binding to STARD13.Computational and mathematical methods in medicine · 2021
    Article
  7. mir-182-5p Regulates Cell Growth of Liver Cancer via Targeting RCAN1.Gastroenterology research and practice · 2021
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Man-Qing CaoDepartment of Hepatobiliary Surgery, Liver Cancer Institute and Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
A-Bin YouKey laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Division of Etiology, Peking University Cancer Hospital and Institute, Haidian District, Beijing, 100142, China.
Xiao-Dong ZhuDepartment of Hepatobiliary Surgery, Liver Cancer Institute and Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Wei ZhangDepartment of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China.
Yuan-Yuan ZhangDepartment of Hepatobiliary Surgery, Liver Cancer Institute and Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Shi-Zhe ZhangDepartment of Hepatobiliary Surgery, Liver Cancer Institute and Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Kei-Wei ZhangDepartment of General Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200092, China.
Hao CaiDepartment of Hepatobiliary Surgery, Liver Cancer Institute and Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Wen-Kai ShiDepartment of Hepatobiliary Surgery, Liver Cancer Institute and Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Xiao-Long LiDepartment of Hepatobiliary Surgery, Liver Cancer Institute and Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Kang-Shuai LiDepartment of Hepatobiliary Surgery, Liver Cancer Institute and Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Dong-Mei GaoDepartment of Hepatobiliary Surgery, Liver Cancer Institute and Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
De-Ning MaDepartment of Colorectal Cancer Surgery, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China.
Bo-Gen YeDepartment of Organ Transplantation, Changhai Hospital, The Second Military Medical University, Shanghai, 200433, China.
Cheng-Hao WangDepartment of Liver Surgery, Fudan University Shanghai Cancer Center, Cancer Hospital, Shanghai, 200032, China.
Cheng-Dong QinDepartment of Breast Cancer Surgery, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China.
Hui-Chan SunDepartment of Hepatobiliary Surgery, Liver Cancer Institute and Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China. sun.huichuan@zs-hospital.sh.cn.
Ti ZhangDepartment of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China. zhangti@tjmuch.com.
Zhao-You TangDepartment of Hepatobiliary Surgery, Liver Cancer Institute and Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China. zytang88@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The original article [1] contains an error in Fig. 5a whereby the Western blot bands representing CyclinD1 have mistakenly been duplicated over the Western blot bands intended to represent SGK.

Identifiers

PMID29669588
PMCPMC5907218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.